Effects of Levosimendan Preconditioning on Left Ventricular Remodeling after Myocardial Reperfusion in Acute Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention
DOI:
https://doi.org/10.1532/hsf.4267Keywords:
levosimendan, acute myocardial infarction, percutaneous coronary intervention, left ventricular remodeling, myocardial reperfusionAbstract
Objective: Levosimendan is a novel drug often used to treat heart failure. We aimed to explore the effects of levosimendan preconditioning on left ventricular remodeling (LVR) after myocardial reperfusion in acute myocardial infarction (AMI) patients receiving the percutaneous coronary intervention (PCI).
Methods: A total of 258 AMI patients treated from January 2018 to September 2020 were randomly divided into control and observation groups. Based on conventional drug therapy, levosimendan was given 30 min before PCI for the observation group, and dobutamine was intravenously injected for the control group. Baseline data, thrombolysis in myocardial infarction (TIMI) blood flow grade, myocardial injury markers, and LVR indices were compared, and the influencing factors for LVR were analyzed.
Results: After treatment, various degrees of blood perfusion were found, and the TIMI grade was better than that before treatment in both groups (P < .05). The levels of aspartate aminotransferase, creatine kinase-MB, cardiac troponin T, and brain natriuretic peptide (BNP) declined in both groups, more significantly in the observation group (P < .05). Left ventricular end-systolic diameter, left ventricular end-diastolic diameter and left ventricular end-diastolic volume declined, whereas left ventricular ejection fraction rose in both groups, more significantly in the observation group (P < .05). Age and BNP were risk factors for LVR, whereas levosimendan preconditioning was a protective factor (P < .05).
Conclusion: Levosimendan preconditioning can protect cardiac function and promote the recovery of the left ventricular structure. Age and BNP are risk factors for LVR after myocardial reperfusion in AMI patients undergoing PCI, and levosimendan preconditioning is a protective factor.
References
Agostoni P, Farmakis DT, García-Pinilla JM, et al. Haemodynamic balance in acute and advanced heart failure: An expert perspective on the role of levosimendan. Card Fail Rev 2019;5:155-161.
Almeida RCM, Jorge AJL, Rosa MLG, et al. Left ventricular remodeling patterns in primary healthcare. Arq Bras Cardiol 2020;114:59-65.
Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guidelines for diagnosis and treatment of acute ST-segment elevation myocardial infarction [in Chinese]. Chin J Cardiol 2015;43:380-393.
Choi KH, Song YB, Lee JM, et al. Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in patients undergoing complex procedures. JACC Cardiovasc Interv 2019;12:607-620.
Elliott J, Kelly SE, Bai Z, et al. Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: Protocol for an umbrella review. BMJ Open 2017;7:e015421.
Faisal SA, Apatov DA, Ramakrishna H, Weiner MM. Levosimendan in cardiac surgery: Evaluating the evidence. J Cardiothorac Vasc Anesth 2019;33:1146-1158.
Kirlidis TT, Skoularigis J, Tsaknakis KT, Karayiannis G, Tsaknakis TK, Triposkiadis F. The influence of beta-blockade on the hemodynamic effects of levosimendan in elderly (>or= 70 years) patients with acutely decompensated systolic heart failure. Int J Clin Pharmacol Ther 2009;47:454-459.
Kreusser MM, Raake PW. Inpatient Therapeutic Options. In: Feldman D, Mohacsi P, eds. Heart Failure. Cardiovascular Medicine. Springer, Cham, Switzerland; 2019; 165-170.
Lan J, Gao GL, Zhang Y. Correlation between thyroid-stimulating hormone levels and left ventricular remodeling in patients with ST-segment elevation myocardial infarction [in Chinese]. Prevent Treat Cardio-Cereb-Vasc Dis 2019;19:497-500.
Li N, Gao X, Wang W, Wang P, Zhu B. Protective effects of recombinant human brain natriuretic peptide on the myocardial injury induced by acute carbon monoxide poisoning. Cardiovasc Diagn Ther 2020;10:1785-1794.
Lin YK, Chen YC, Chen YA, Huang JH, Chen SA, Chen YJ. Levosimendan differentially modulates electrophysiological activities of sinoatrial nodes, pulmonary veins, and the left and right atria. J Cardiovasc Electrophysiol 2018;29:1150-1158.
Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017;376:2032-2042.
Meng JB, Hu MH, Lai ZZ, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: A randomized controlled trial. Med Sci Monit 2016;22:1486-1496.
van Diepen S, Mehta RH, Leimberger JD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg 2020;159:2302-2309.e6.
Zhou S, Zhang L, Li J. Effect of levosimendan in patients with acute decompensated heart failure: A meta-analysis. Herz 2019;44:630-636.
